Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
NCT00203424
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
23
Enrollment
OTHER
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
Erlotinib + Bevacizumab
Sponsor
Translational Oncology Research International
Collaborators
[object Object]